Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. [electronic resource]
Producer: 20160519Description: 998-1005 p. digitalISSN:- 1569-8041
- Administration, Oral
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- administration & dosage
- Asia
- Biomarkers, Tumor -- antagonists & inhibitors
- Biotransformation
- Carcinoma, Non-Small-Cell Lung -- blood
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- ErbB Receptors -- genetics
- Female
- Half-Life
- Humans
- Lung Neoplasms -- blood
- Male
- Maximum Tolerated Dose
- Metabolic Clearance Rate
- Middle Aged
- Molecular Targeted Therapy
- Mutation
- Phosphorylation
- STAT3 Transcription Factor -- antagonists & inhibitors
- Signal Transduction -- drug effects
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.